N-(4-hydroxy-2,3,6-trimethylphenyl)-formamide | 99075-42-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-hydroxy-2,3,6-trimethylphenyl)-formamide
• 英文别名: 4-Formamino-2.3.5-trimethyl-phenol；4-formylamino-2,3,5-trimethylphenol；formic acid-(4-hydroxy-2,3,6-trimethyl-anilide)；Ameisensaeure-(4-hydroxy-2,3,6-trimethyl-anilid)；N-(4-hydroxy-2,3,6-trimethylphenyl)formamide
• CAS: 99075-42-0
• 化学式: C₁₀H₁₃NO₂
• 分子量: 179.219
• InChiKey: GOFKUPUHFLPRKX-UHFFFAOYSA-N

物化性质

• 熔点：
  216-219 °C(Solv: water (7732-18-5))
• 沸点：
  405.5±45.0 °C(Predicted)
• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4-hydroxy-2,3,6-trimethylphenyl)-formamide 在 盐酸 、 potassium carbonate 、 N,N-二乙基苯胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 YT-15
  参考文献：
  名称：

  5-Aminocoumarans:  Dual Inhibitors of Lipid Peroxidation and Dopamine Release with Protective Effects against Central Nervous System Trauma and Ischemia

  摘要：

  A series of 2,3-dihydro-5-benzofuranamines (5-aminocoumarans) were developed for the treatment of traumatic and ischemic central. nervous system (CNS) injury. Compounds within this class were extremely effective inhibitors of lipid peroxidation in vitro and antagonized excitatory behavior coupled with peroxidative injury induced by spinal intrathecal injection of FeCl2 (mouse-FeCl2-it assay) in vivo. Selected compounds were tested for antagonistic activity on methamphetamine (MAP)-induced hypermotility resulting from dopamine release in the mouse brain. Among the compounds synthesized, compound 26n (2,3-dihydro-2,4,6,7-tetramethyl-2-[(4-phenyl-1-piperidinyl)meth]-5-benzofuranamine) exhibited potent effects in these assays (inhibition of lipid peroxidation, IC50 = 0.07 mu M; mouse-FeCl2-it assay, ID50 = 10.4 mg/kg, po; MAP-induced hypermotility, 98% inhibition, 10 mg/kg, ip). The S-(+)-form of compound 26n dihydrochloride (TAK-218), which has 30 times more potent antagonistic activity on MAP-induced hypermotility than the R-(-)-form, improved more significantly the survival rate in the cerebral ischemia model (rat, 1-3 mg/kg, ip) during the period of 1-14 days after ischemia and decreased functional disorders in the traumatic brain injury model (rat, 0.1-1 mg/kg, ip) 3-14 days after injury. These results imply a role for dopamine in deterioration of CNS function after ischemic and traumatic injury. TAK-218 is a promising compound for the treatment of stroke and CNS trauma and is now under clinical investigation.

  DOI：

  10.1021/jm960411j
• 作为产物：
  描述：

  4-氨基-2,3,5-三甲基苯酚 以 甲酸 为溶剂， 生成 N-(4-hydroxy-2,3,6-trimethylphenyl)-formamide
  参考文献：
  名称：

  Aminocoumaran derivatives, their production and use

  摘要：

  一种一般式（I）的新型氨基香豆素衍生物：##STR1##其中R.sup.1和R.sup.2是氢原子、酰基、烷氧羰基、脂肪基或芳香基；R.sup.3、R.sup.4和R.sup.5是可选酰化的羟基、可选取代的氨基、烷氧基或脂肪基，或者R.sup.3、R.sup.4和R.sup.5中的两个可以连接在一起形成一个碳环基团；R.sup.6和R.sup.7是脂肪基，其中至少一个在α-位置有一个亚甲基基团；R.sup.8和R.sup.9是氢原子或脂肪基或芳香基，或其盐，用于预防和治疗各种疾病，如动脉硬化、肝病、脑血管疾病等。

  公开号：

  US05376681A1

文献信息

• Benzofuran derivatives, their production and use
  申请人：——

  公开号：US20020160996A1

  公开（公告）日：2002-10-31

  Compounds represented by the formula: 1 wherein R 1 and R 2 are hydrogen atom, a hydrocarbon group or a heterocyclic group, or R 1 and R 2 may form, together with the adjacent carbon atom, a 3- to 8-membered homocyclic or heterocyclic ring, W indicates (i) a group represented by the formula: 2 wherein ring B indicates a 5- to 7-membered ring, or (ii) a group represented by the formula: 3 wherein R 4 indicates (1) an aliphatic hydrocarbon group, which may be substituted with an aromatic group, or (2) an acyl group containing an aromatic group, R 5 is hydrogen atom, a C 1-6 alkyl, or an acyl group, provided that, when W is Wa, R 3 is hydrogen atom, a hydrocarbon group or a heterocyclic group, when W is Wb, R 3 indicates a C 6-14 aryl group, or salts thereof or prodrugs thereof have an excellent action to inhibit neurodegeneration and the like as well as an excellent brain penetrability and are low in the toxicity, thereby being useful as prophylactic or therapeutic drugs for nerve degenerative diseases and the like.

  由以下公式代表的化合物： 其中 R1 和 R2 是氢原子、烃基或杂环基，或者 R1 和 R2 可以与相邻的碳原子一起形成 3 至 8 个成员的同环或杂环环，W 表示 (i) 由以下公式代表的基团： 其中环 B 表示一个 5 至 7 个成员的环，或者 (ii) 由以下公式代表的基团： 其中 R4 表示 (1) 可以用芳香基取代的脂肪烃基，或者 (2) 含有芳香基的酰基，R5 是氢原子、C1-6 烷基或酰基，提供当 W 是 Wa 时，R3 是氢原子、烃基或杂环基，当 W 是 Wb 时，R3 表示一个 C6-14 芳基，或其盐或前药具有优异的抑制神经退行性等作用，以及出色的脑透过性，毒性低，因此可用作预防或治疗神经退行性疾病等的药物。
• Assessing doctors' competence: application of CUSUM technique in monitoring doctors' performance
  作者：T. O. LIM、A. SORAYA、L. M. DING、Z. MORAD

  DOI：10.1093/oxfordjournals.intqhc.a002616

  日期：2002.6.1

  Background. Quality assurance of medical practice requires assessment of doctors’ performance, whether informally via a system such as peer review or more formally via one such as credentialing. Current methods of assessment are, however, subjective or implicit. More objective methods of assessment based on statistical process control technique such as cumulative sum procedure (CUSUM) may be helpful. Objective. To determine the usefulness and acceptability of CUSUM charting for assessing doctors’ performance. Method. We applied CUSUM charting to assess doctors’ performance of endoscopic retrograde pancreatography, renal and breast biopsies, thyroidectomy, and instrumental delivery. A CUSUM chart is a graphical representation of the trend in the outcome of a series of consecutive procedures. At acceptable levels of performance, the CUSUM curve is flat, while at unacceptable levels of performance, the curve slopes upward and eventually crosses a decision interval. When this occurs, the CUSUM chart indicates unsatisfactory performance. Thus, it provides an early warning of an adverse trend. Results. All participating doctors found the technique useful to objectively measure their proficiency. CUSUM charts showed the progress of trainees in acquiring new skills. As they become more skilful with training, their CUSUM curves flatten. Among consultants, level CUSUM curves demonstrated ongoing maintenance of competence. All participants found the technique acceptable as a self-assessment tool. They were, however, less certain of its acceptability as a basis for credentialing. Conclusion. We recommend the use of CUSUM charting as a tool for personal audit at an individual level. It may also be used to show proof of technical competence for the purpose of credentialing.

  背景。要保证医疗质量，就必须对医生的工作表现进行评估，无论是通过同行评议等非正式制度，还是通过资格认证等正式制度。然而，目前的评估方法都是主观或隐含的。基于统计过程控制技术（如累积总和程序）的更客观的评估方法可能会有所帮助。目标。确定 CUSUM 图表在评估医生绩效方面的实用性和可接受性。方法。我们应用 CUSUM 图表评估医生在内镜逆行胰腺造影术、肾脏和乳腺活组织检查、甲状腺切除术和器械接生中的表现。CUSUM 图表是一系列连续手术结果趋势的图形表示。在可接受的绩效水平下，CUSUM 曲线是平的，而在不可接受的绩效水平下，曲线会向上倾斜并最终越过决策区间。当出现这种情况时，CUSUM 图表就会显示出不理想的绩效。因此，它提供了不利趋势的预警。结果所有参与调查的医生都认为这项技术有助于客观衡量他们的工作能力。CUSUM 图表显示了学员在掌握新技能方面取得的进步。随着受训医生的技能不断提高，他们的 CUSUM 曲线也逐渐趋于平缓。在顾问中，水平 CUSUM 曲线显示了能力的持续保持。所有参与者都认为，该技术作为一种自我评估工具是可以接受的。不过，他们不太确定该技术是否可作为资格认证的依据。结论我们建议使用 CUSUM 图表作为个人层面的个人审核工具。它还可用于证明技术能力，以便进行资格认证。
• Intermediates for pharmaceutically useful aminocoumaran derivatives
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05594154A1

  公开（公告）日：1997-01-14

  A novel aminocoumaran derivative of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are a hydrogen atom, an acyl group, an alkoxycarbonyl group, an aliphatic group or aromatic group; R.sup.3, R.sup.4 and R.sup.5 are an optionally acylated hydroxyl optionally substituted amino group, alkoxy group or aliphatic group, or two of R.sup.3, R.sup.4 and R.sup.5 may be linked together to form a carbocyclic group; R.sup.6 and R.sup.7 are an aliphatic group and at least one of them has a methylene group at the .alpha.-position; R.sup.8 and R.sup.9 are a hydrogen atom or an aliphatic group or aromatic group, or a salt thereof is useful for medicines for preventing and treating various diseases such as arterial sclerosis, hepatopathy, cerebrovascular diseases and the like.

  一种新型氨基香豆素衍生物的一般式为（I）：##STR1## 其中，R.sup.1和R.sup.2是氢原子、酰基、烷氧羰基、脂肪基或芳基；R.sup.3、R.sup.4和R.sup.5是一个可选酰化的羟基、可选取代的氨基、烷氧基或脂肪基，或R.sup.3、R.sup.4和R.sup.5中的两个可连接在一起形成碳环基；R.sup.6和R.sup.7是脂肪基，其中至少一个在α位上有一个亚甲基；R.sup.8和R.sup.9是氢原子或脂肪基或芳基，或其盐，可用于预防和治疗各种疾病，如动脉硬化、肝病、脑血管疾病等。
• Process for preparing optically active 2,3-dihydrobenzofuran compounds
  申请人：——

  公开号：US20040077712A1

  公开（公告）日：2004-04-22

  A process for preparing optically active 2,3-dihydrobenzofuran compounds which comprises subjecting a 2,3-dihydrobenzofuran compound represented by the general formula or a salt thereof to optical resolution with an optically active acid compound: 1 [wherein R 1 and R 2 are each hydrogen or an optionally substituted hydrocarbon group; R 3 is an optionally substituted aromatic group; and C is a benzene ring which may further have a substituent in addition to the amino group]. The process enables industrially advantageous production of intermediates for the synthesis of optically active 2,3-dihydrobenzofuran compounds useful as preventive and/or therapeutic drugs for neurodegenerative diseases and so on.

  一种制备光学活性2,3-二氢苯并呋喃化合物的方法，包括将一般式所表示的2,3-二氢苯并呋喃化合物或其盐与光学活性酸化合物进行光学分辨：1 [其中R1和R2均为氢或可选取代的碳氢基团；R3为可选取代的芳香基团；C为苯环，除氨基外还可能有取代基]。该方法可实现工业上优势的中间体生产，用于合成对神经退行性疾病等有预防和/或治疗作用的光学活性2,3-二氢苯并呋喃化合物。
• Method of using aminocoumaran derivatives for treating cerebrovascular
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05478844A1

  公开（公告）日：1995-12-26

  A novel aminocoumaran derivatives of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are a hydrogen atom, an acyl group, an alkoxycarbonyl group, an aliphatic group or aromatic group; R.sup.3, R.sup.4 and R.sup.5 are an optionally acylated hydroxyl optionally substituted amino group, alkoxy group or aliphatic group, or two of R.sup.3, R.sup.4 and R.sup.5 may be linked together to form a carbocyclic group; R.sup.6 and R.sup.7 are an aliphatic group and at least: one of them has a methylene group at the .alpha.-position; R.sup.8 and R.sup.9 are a hydrogen atom or an aliphatic group or aromatic group, or a salt thereof is useful for medicines for treating various diseases such as arterial sclerosis, hepatopathy, cerebrovascular diseases and the like.

  一种新型氨基香豆素衍生物，其通式为(I)：##STR1## 其中R.sup.1和R.sup.2为氢原子、酰基、烷氧基羰基、脂肪基或芳香族基；R.sup.3、R.sup.4和R.sup.5为可选的酰化羟基、可选的取代氨基、烷氧基或脂肪基，或者R.sup.3、R.sup.4和R.sup.5中的两个可以连接在一起形成一个环状碳骨架；R.sup.6和R.sup.7为脂肪基，至少其中一个在α-位上有一个亚甲基；R.sup.8和R.sup.9为氢原子、脂肪基或芳香族基，或其盐，用于治疗各种疾病，如动脉硬化、肝病、脑血管疾病等。